SYDNEY, July 12, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the launch of its Scientific Advisory Board (SAB). The new SAB is comprised of four distinguished clinicians and scientists with expertise in developing innovative therapies for brain cancer.
- SAB will advise and guide Kazia as paxalisib progresses towards the planned completion of GBM AGILE at 2H CY2023 and potential commercialization thereafter.
- SAB members are leading experts in the field of brain cancer, with a long history of research and publication. Initial membership includes:
- Doctor Priscilla Brastianos [Massachusetts General Hospital]
- Doctor Jean de Groot [University of California, San Francisco]
- Doctor Alan Olivero [independent consultant and inventor of paxalisib]
- Doctor Patrick Wen [Dana-Farber Cancer Institute]
CEO of Kazia, Dr. James Garnersaid: “We are both delighted and extremely honored to have four highly respected brain cancer specialists join the new Kazia SAB. As paxalisib progresses rapidly towards potential commercialization, guidance from experts in the field will be critical to our success. We could not wish for any more qualified group of advisors than the four people who have joined us.”
Dr Garner added: “We are grateful to the four former SAB members of Kazia: Professor Sir Murray Brenandoctor Karen FerranteTeacher Peter Gunningand Dr. Alex Matter. Their generous and thoughtful advice has helped make Kazia the company it is today. Given that paxalisib is now in an advanced stage of development, it seems appropriate to reform BAS now in the context of the drug’s anticipated commercial market. »
Doctor Priscilla Brastianos
Doctor Priscilla Brastianos is director of the Central Nervous System Metastasis Center at Massachusetts General Hospital and runs a multi-R01 funded lab. Her research focuses on understanding the genomic mechanisms underlying primary and metastatic brain tumors and she has led studies that have identified novel therapeutic targets in brain tumors.
Doctor Priscilla Brastianos completed medical school and internal medicine residency at Johns Hopkins School of Medicine and postgraduate training in hematology/oncology and neuro-oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital. She has more than 145 scientific publications and has translated her scientific findings into multicenter national trials. She also directs a multidisciplinary central nervous system metastasis clinic at Massachusetts General Hospital / Harvard Medical School. She has received numerous awards for her work, including the American Association for Cancer Research’s “NextGen Star” award, the Damon Runyon Clinical Investigator Award, the Breast Cancer Research Foundation Award, the Susan G. Komen Career Catalyst Award, the American Brain Tumor Association Joel Gingras Award and the Anne Klibanski Award for Excellence in Mentoring.
Doctor Jean de Groot
Doctor Jean de Groot is Division Chief of the Neuro-Oncology Division within the Neurological Surgery Department of the hospital University of California, San Francisco (UCSF). He is a neuro-oncologist with extensive experience in clinical and translational research in the field of glioma, angiogenesis, molecular targeted therapy and immunotherapy.
Prior to joining UCSF, Dr. de Groot was based at the MD Anderson Cancer Center in Houston, TX, where he was co-responsible for the GBM Moonshot program. He has authored more than 135 peer-reviewed publications, has been the principal investigator of 44 clinical trials, has collaborated on 78 other clinical trials, and has been the recipient of multiple grants from NCI, CPRIT, NBTS, and industry. He has also served as a reviewer for 23 scientific journals and sits on four editorial review boards, in addition to holding several leadership positions with the Society for Neuro-Oncology (SNO).
Doctor Alan Olivero
Doctor Alan Olivero is a consultant specializing in drug discovery and development. In 2018, he retired from Genentech, Inc., where he worked for 25 years, rising to the level of Senior Director of Discovery Chemistry and Head of Research Operations. While at Genentech, he oversaw much of the medicinal chemistry conducted at Genentech, led research teams for eight clinical candidates, and as head of research operations also oversaw the research budget, staffing and the company’s research facilities.
Dr. Olivero is an expert in intracellular signaling pathways and was the team leader of Genentech’s PI3K franchise. He has a specialist interest in brain cancer and is a co-inventor of paxalisib (formerly GDC-0084). He led the early development of paxalisib and was responsible for getting the drug into human trials.
Dr. Olivero holds a bachelor’s degree in chemistry from Stanford Universitycompleted postgraduate studies in synthetic organic chemistry at Swiss Federal Institute of Technology in Zürich (ETHZ), and obtained his doctorate in organic chemistry from Stanford University in 1988. He has co-authored numerous scientific publications and is a named inventor on over 40 patents.
Doctor Patrick Wen
Doctor Patrick Y. Wen is a professor of neurology at Harvard Medical School and director of the Neuro-Oncology Center at the Dana-Farber Cancer Institute. His research interests include novel therapies for brain tumors, as well as innovative clinical trial designs, and response assessment and endpoints in clinical trials.
Dr. Wen served as President of the Society for Neuro-Oncology (SNO) from 2017 to 2019. He was previously Editor-in-Chief of Neuro-Oncology and is currently SNO’s Editor-in-Chief of Neuro-Oncology. He is also a member of the steering committee of the Response Assessment in Neuro-Oncology (RANO) working group and co-chair of the agent selection committee for the GBM-AGILE trial.
After earning his medical degree from the Medical College of St. Bartholomew’s Hospital at the University of LondonDr. Wen completed residency training at the Harvard Longwood Neurology Training Program and completed his clinical fellowship and neurology research fellowship at the Center for Neurologic Diseases, Brigham and Women’s Hospital, in Boston, MA.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrating inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat glioblastoma, the most common and aggressive form of primary brain cancer in adult. Licensed to Genentech in late 2016, paxalisib began enrollment for GBM AGILE, a pivotal glioblastoma study, in January 2021. Seven additional studies are active in various forms of brain cancer. Paxalisib received orphan drug designation for glioblastoma from the U.S. FDA in February 2018and Fast Track Designation for glioblastoma by the US FDA in August 2020. Additionally, paxalisib has been granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020and for AT/RT in June 2022.
Kazia is also developing EVT801, a small molecule VEGFR3 inhibitor, which was licensed from Evotec SE in April 2021. Preclinical data showed that EVT801 is active against a wide range of tumor types and provided compelling evidence of synergy with immuno-oncology agents. A phase I study began recruitment in November 2021.
For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx.
This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as “may”, “intends”, “potential”, “forward-looking” or other similar words. Any statements describing Kazia’s future plans, strategies, intentions, expectations, objectives, goals or prospects, as well as other statements that are not historical facts, are also forward-looking statements. These statements are based on Kazia’s expectations and projections regarding future events and trends affecting our business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical trials and product development and the impact of global economic conditions. These and other risks and uncertainties are described in greater detail in Kazia’s Annual Report, filed on Form 20-F with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this announcement. Actual results could differ materially from those discussed in this announcement.
This document has been authorized for distribution to the ASX by James Garnergeneral manager, general manager.
See original content to download multimedia: https://www.prnewswire.com/news-releases/kazia-launches-new-scientific-advisory-board-comprised-of-world-leading-experts-in-brain-cancer -301583562.html
SOURCE Kazia Therapeutics Limited